Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues.

J Asp1, C Brantsing, M S Benassi

  • 1Research Center for Endocrinology and Metabolism, Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.

International Journal of Cancer
|July 31, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MuSA: a Nextflow pipeline for deep, reproducible annotation and clinical ranking of genomic variants.

BMC bioinformatics·2026
Same author

SATURN: assessing the feasibility of utilising existing registries for real-world evidence data collection to meet patients, regulatory, health technology assessment and payer requirements.

Orphanet journal of rare diseases·2024
Same author

Project SATURN- a real-world evidence data collaboration with existing European datasets in Osteogenesis Imperfecta to support future therapies.

Orphanet journal of rare diseases·2024
Same author

Defining priorities in the transition from paediatric to adult healthcare for rare bone disease patients: a dialogic approach.

European journal of medical genetics·2023
Same author

A randomized, triple-blinded controlled clinical study with a novel disease-modifying drug combination in equine lameness-associated osteoarthritis.

Osteoarthritis and cartilage open·2023
Same author

Biglycan neo-epitope (BGN<sup>262</sup>), a novel biomarker for screening early changes in equine osteoarthritic subchondral bone.

Osteoarthritis and cartilage·2022

Genetic alterations of the p14(ARF) gene are rare in chondrosarcoma. Researchers found no mutations or methylation, with only one deletion, suggesting p14(ARF) is not a primary driver in this cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The p16 gene locus also encodes p14(ARF), a protein that stabilizes p53.
  • Alterations in the p14(ARF) gene are implicated in various cancers.
  • Chondrosarcoma is a bone cancer where genetic alterations are being investigated.

Purpose of the Study:

  • To investigate genetic alterations in the first unique exon (exon 1 beta) of the p14(ARF) gene in chondrosarcoma tissues.
  • To determine the frequency of mutations, deletions, and methylation in p14(ARF) in chondrosarcoma.

Main Methods:

  • Polymerase chain reaction (PCR) was used to amplify exon 1 beta of p14(ARF).
  • DNA sequencing was performed to identify mutations.
  • Methylation-specific PCR was employed to detect promoter methylation.

Related Experiment Videos

Main Results:

  • Out of 22 chondrosarcoma tissues analyzed, one case exhibited homozygous deletion of exon 1 beta.
  • No mutations were detected in the p14(ARF) exon 1 beta across all samples.
  • No evidence of methylation in the p14(ARF) promoter region was found.

Conclusions:

  • Genetic alterations, specifically mutations and methylation, in the p14(ARF) gene appear to be infrequent in chondrosarcoma.
  • Homozygous deletion of exon 1 beta is a rare event in this cancer type.
  • These findings suggest that p14(ARF) genetic changes are not a common driver in the development of chondrosarcoma.